Gan & Lee Pharmaceuticals Co., Ltd.SSE: 603087

(603087)"Gan & Lee Pharmaceuticals"Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Cartridge) in El Salvador

· Issued by Gan & Lee Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 603087 · · 2 pages · Chinese

Summary by 6ix AI

Gan & Lee Pharmaceuticals Co., Ltd. announced the acquisition of pharmaceutical registration approval for Insulin Glargine Injection in El Salvador. The approval allows the company to sell this insulin product in the Salvadoran market, which is significant for diabetes treatment. Investors are cautioned about uncertainties related to market demand and competition affecting sales in El Salvador.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

On 6ix: 6ix.com/news/603087gan-and-lee-pharmaceuticalsannouncement-on-acquisition-of-pharmaceutical-registration-approval-for-insulin-glargine-injection-cartridge-in-el-salvador

Release

Announcement on Acquisition of Pharmaceutical Registration Approval for Insulin Glargine Injection (Cartridge) in El Salvador

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Gan & Lee Pharmaceuticals Co., Ltd. on 6ix

Story so far

Earlier from Gan & Lee Pharmaceuticals

All Gan & Lee Pharmaceuticals news releases